Dexcom Inc
XMUN:DC4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dexcom Inc
XMUN:DC4
|
US |
|
E
|
EDP Energias de Portugal SA
SWB:EDP
|
PT |
|
W
|
Wharf Holdings Ltd
HKEX:4
|
HK |
|
R
|
Re/Max Holdings Inc
XBER:2RM
|
US |
|
V
|
Visteon Corp
XMUN:VS51
|
US |
|
D
|
D R Horton Inc
XBER:HO2
|
US |
|
M
|
Merck & Co Inc
XHAM:6MK
|
US |
|
A
|
Ally Financial Inc
LSE:0HD0
|
US |
Dexcom Inc
Dexcom makes continuous glucose monitoring systems for people with diabetes. Its core product is a small wearable sensor that tracks glucose levels through the day and sends readings to a smartphone, receiver, or insulin pump, so users can manage blood sugar without repeated finger sticks. The company also sells the software and connected apps that display trends and alerts. Its main customers are people with diabetes, along with the doctors, clinics, hospitals, and insurance plans that recommend, prescribe, or reimburse the devices. Dexcom makes money mostly by selling the disposable sensors and other consumables that patients replace regularly, plus related receivers and accessories. That gives the business a recurring revenue pattern rather than a one-time device sale. What makes Dexcom different is that it sits between medical devices and digital health. It does not just make hardware; it sells an ongoing monitoring service built around data, alerts, and software that help patients and caregivers respond quickly to glucose changes. In the diabetes care chain, Dexcom is a key provider of real-time glucose data used to guide daily treatment decisions.
Dexcom makes continuous glucose monitoring systems for people with diabetes. Its core product is a small wearable sensor that tracks glucose levels through the day and sends readings to a smartphone, receiver, or insulin pump, so users can manage blood sugar without repeated finger sticks. The company also sells the software and connected apps that display trends and alerts.
Its main customers are people with diabetes, along with the doctors, clinics, hospitals, and insurance plans that recommend, prescribe, or reimburse the devices. Dexcom makes money mostly by selling the disposable sensors and other consumables that patients replace regularly, plus related receivers and accessories. That gives the business a recurring revenue pattern rather than a one-time device sale.
What makes Dexcom different is that it sits between medical devices and digital health. It does not just make hardware; it sells an ongoing monitoring service built around data, alerts, and software that help patients and caregivers respond quickly to glucose changes. In the diabetes care chain, Dexcom is a key provider of real-time glucose data used to guide daily treatment decisions.
Revenue: Dexcom reported second-quarter revenue of $1.31 billion, up 13% year over year on a reported basis and 12% organically, with growth led by strong U.S. and international demand.
Guidance: Management raised full-year revenue guidance to $5.18 billion to $5.25 billion and also lifted gross margin, operating margin, and EBITDA margin targets.
Demand: New customer starts stayed at a record level globally, with a sequential uptick in the U.S. and broad-based strength across patient groups.
Coverage: The company said its CONNECT trial strengthens the case for broader reimbursement in non-insulin type 2 diabetes and that it has already submitted the data to CMS.
Products: Dexcom highlighted the launch of the redesigned Stelo app, progress on Smart Basal, the rollout of G7 15 Day, and Health Canada’s clearance of G7 15 Day.
Cash Return: Dexcom generated over $600 million of free cash flow in the first half and repurchased about $600 million of stock in Q2 under its $1 billion buyback plan.
